CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Real-time Estimate Cboe BZX Other stock markets 18:17:15 15/07/2025 BST			5-day change	1st Jan Change
154.46 ^USD	-2.27%		-2.15%	-16.05%

07-09	Evercore ISI Adjusts PT on Charles River Laboratories International to $180 From $170	MT
07-09	Tariff Drama, Minimal Market Reaction

Charles River Laboratories International, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10:00 AM

Published on 09/06/2025 at 15:51, updated on 09/06/2025 at 16:06

Presenter Speech
Max Smock (Analysts)

All right. Good morning, everyone, and thanks for joining us for the management presentation. My name is Max Smock, and I'm the research analyst here at William

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Charles River Laboratories International, Inc.

Evercore ISI Adjusts PT on Charles River Laboratories International to $180 From $170	07-09	MT
Tariff Drama, Minimal Market Reaction	07-09
Citigroup Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts PT to $200 From $150	07-09	MT
Analyst recommendations: Illumina, Freeport-McMoran, XPO, T-Mobile US…	07-09
Myrtelle Inc. Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen Vector Core	07-08	CI
Charles River Laboratories International, Inc., Q1 2025 Earnings Call, May 07, 2025	06-19
Charles River Laboratories International, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10:00 AM	06-09
Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 10:30 AM	06-04
Charles River Laboratories International to Seek Strategic M&A	06-03	CI
Charles River Laboratories, CHDI Foundation Extend Collaboration	05-28	MT
Charles River Laboratories International Extend Drug Discovery Partnership With CHDI Foundation	05-28	RE
Charles River Laboratories International CEO James C. Foster's Employment Extended Until February 2027 - SEC Filing	05-23	RE
Declaration of Voting Results by Charles River Laboratories International	05-23	CI
Trump's Tariff Blitz Roils Markets, Targets EU and Apple	05-23
Redburn Atlantic Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $182 From $188	05-23	MT
Analyst recommendations: Crowdstrike, AMD, Boeing, Intuit, Okta…	05-23
Charles River Laboratories International, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08:40 AM	05-14
TD Cowen Upgrades Charles River Laboratories International to Buy From Hold, Adjusts PT to $179 From $105	05-14	MT
Morgan Stanley Cuts Price Target on Charles River Laboratories International to $168 From $184	05-09	MT
UBS Cuts Price Target on Charles River Laboratories International to $150 From $185, Keeps Neutral Rating	05-08	MT
Barclays Adjusts Price Target on Charles River Laboratories International to $155 From $145, Maintains Equalweight Rating	05-08	MT
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $180 From $140, Maintains Buy Rating	05-08	MT
London Calling: Markets Jump	05-08
Jefferies Adjusts Price Target on Charles River Laboratories International to $142 From $100, Maintains Hold Rating	05-08	MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $145 From $165, Maintains Neutral Rating	05-08	MT